Drug profile · INN
rofecoxib
VIOXX
rofecoxib (VIOXX) is a cyclooxygenase-2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — rofecoxib
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
rofecoxib (VIOXX) is a cyclooxygenase-2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cyclooxygenase-2 inhibitor
Primary target: Prostaglandin G/H synthase 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is rofecoxib?
rofecoxib (VIOXX) is a cyclooxygenase-2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for rofecoxib?
VIOXX is a marketed brand name for rofecoxib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rofecoxib?
rofecoxib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.